Theragenics Launches Torx™ Transitionless Guidewires
Theragenics Launches Torx™ Transitionless Guidewires
Innovative Addition to our Galt Guidewire Products
BUFORD, Ga.--(BUSINESS WIRE)-- Theragenics Corporation® (NYS: TGX) , a medical device company serving the surgical products and prostate cancer treatment markets, today announced that Galt Medical (a wholly-owned subsidiary of Theragenics) launched its Torx™ transitionless guidewire line. The Torx™ guidewire uses a proprietary transitionless construction for improved navigation during challenging interventional cases. The Torx™ guidewire has a number of features including a solid Nitinol core which provides flexibility and kink resistance, a Galt Gold™ coiled tip that allows for enhanced visualization, and a coating designed for maximum control and durability throughout the procedure. The Torx™ line of guidewires is available in a variety of diameters, tip lengths, and angles for a wide range of applications. In 2009, IMS Health, a leading provider of information services for the healthcare industry, estimated that the U.S. transitionless guidewire market was $1 million annually with a 30% annual growth rate.
"The Torx™ guidewire is a great addition to Galt's comprehensive line of guidewires," said M. Christine Jacobs, Chairman and Chief Executive Officer of Theragenics Corporation. "This product line shows our commitment to providing health care providers with innovative, niche products in growing markets. These types of products will continue to be a focus for us in the future."
Galt Medical, along with NeedleTech Products and CP Medical, comprise Theragenics' surgical products business segment.
Theragenics Corporation (NYS: TGX) operates two business segments: its surgical products business and its brachytherapy seed business. The surgical products business (www.cpmedical.com, www.galtmedical.com, www.needletech.com) manufactures and distributes wound closure, vascular access, and specialty needle products. Wound closure products include sutures, needles and other surgical products. Vascular access includes introducers, guidewires and related products. Specialty needles include coaxial, biopsy, spinal and disposable veress needles, access trocars, implanters, introducer products, and other needle-based products. The surgical products segment serves a number of markets and applications, including, among other areas, interventional cardiology, interventional radiology, vascular surgery, orthopedics, plastic surgery, dental surgery, urology, veterinary medicine, pain management, endoscopy, and spinal surgery. Theragenics' brachytherapy business manufactures, custom loads, distributes and markets "seeds" used primarily in the minimally invasive treatment of localized prostate cancer. The Company's brachytherapy product line (www.theragenicsbrachy.com) includes its palladium-103 TheraSeed® device, its iodine-125 AgX100® device and related services. The terms "Company," "we," "us," or "our" mean Theragenics Corporation and all entities included in our consolidated financial statements. For additional information, call our Investor Relations Department at (800) 998-8479 or visit www.theragenics.com.
This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding estimated market sizes and expected growth in market sizes. Actual results may differ materially due to a variety of factors, including, among other things, risks and uncertainties related to competition within the medical device industry, development and growth of new applications within the medical device markets, new product development cycles, effectiveness and execution of marketing and sales programs, changes in product pricing, continued acceptance of and demand for our products by the markets in which we operate, introduction and/or availability of competitive products by others, potential changes in third-party reimbursement, legislative changes to healthcare markets and industries such as the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act (including provisions such as the medical device tax), uncertainties associated with forecasting demand for a new product, the development and pricing of competing products by competitors, uncertainties and unanticipated costs in connection with the manufacturing and marketing of the Galt Torx™ Guidewire, effectiveness in accessing new customers and new applications, and other factors set forth from time to time in our filings with the Securities and Exchange Commission.
All forward looking statements and cautionary statements included in this document are made as of the date hereof based on information available to us as of the date hereof, and we assume no obligation to update any forward looking statement or cautionary statement.
Frank Tarallo, CFO & Treasurer or Lisa Rassel, Manager of Investor Relations
Phone: 800-998-8479 - 770-271-0233
KEYWORDS: United States North America Georgia
The article Theragenics Launches Torx™ Transitionless Guidewires originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.